methyl (E,3S^*,5R^*)-3,5-dihydroxy-7-phenyl-6-heptenoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂醇
• 英文名称: methyl (E,3S^*,5R^*)-3,5-dihydroxy-7-phenyl-6-heptenoate
• 英文别名: methyl cis-3,5-dihydroxy-7-phenylhept-6-enoate；methyl (E,3S,5R)-3,5-dihydroxy-7-phenylhept-6-enoate
• 化学式: C₁₄H₁₈O₄
• 分子量: 250.295
• InChiKey: VCNWJEZPTFGKLI-FVWNJDPFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl (E,3S^*,5R^*)-3,5-dihydroxy-7-phenyl-6-heptenoate 生成 (4S,6R,E)-4-hydroxy-6-(2-phenylethenyl)-tetrahydropyran-2-one
  参考文献：
  名称：

  KAPA, PRASAD K.

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl (E,3S,5R)-3,5-bis[[tert-butyl(diphenyl)silyl]oxy]-7-phenylhept-6-enoate 生成 methyl (E,3S^*,5R^*)-3,5-dihydroxy-7-phenyl-6-heptenoate
  参考文献：
  名称：

  KAPA, PRASAD K.

  摘要：

  DOI：

文献信息

• Stereoselective Reduction of<i>β</i>,<i>δ</i>-Diketo Esters. A Novel Strategy for the Synthesis of Artificial HMG-CoA Reductase Inhibitors
  作者：Tamejiro Hiyama、Guntoori Bhaskar Reddy、Tatsuya Minami、Takeshi Hanamoto

  DOI：10.1246/bcsj.68.350

  日期：1995.1

  Condensation of N-methoxy-N-methyl amides with the dianions of acetoacetates gives in good yields β,δ-diketo esters, which are reduced with Et2BOMe–NaBH4 in tetrahydrofuran–methanol highly selectively to give syn-β,δ-dihydroxy esters in one step. Similarly, the β,δ-diketo esters of the Taber’s chiral alcohol or its enantiomer respectively are reduced to give syn-β,δ-dihydroxy esters of moderate enantiomeric excess. Higher diastereo- and enantioselectivity were achieved by reduction of the β,δ-diketo esters of the Taber’s chiral alcohol or its enantiomer successively with diisobutylalane and with Et2BOMe–NaBH4. The resulting syn-diol esters were hydrolyzed and lactonized to give various types of β-hydroxy-δ-lactones commonly found in artificial HMG-CoA reductase inhibitors.

  N-甲氧基-N-甲基酰胺与乙酰乙酸酯的二阴离子缩合，高产率地得到了β，δ-二酮酯，这些二酮酯在四氢呋喃-甲醇中与Et2BOMe-NaBH4还原，高度选择性地一步得到syn-β，δ-二羟基酯。类似地，Taber的手性醇或其对映体的β，δ-二酮酯分别还原得到中等对映体纯度的syn-β,δ-二羟基酯。通过先后使用二异丁基铝烷和Et2BOMe-NaBH4还原Taber的手性醇或其对映体的β,δ-二酮酯，获得了更高的非对映选择性和对映选择性。得到的syn-二醇酯经水解和内酯化得到多种常见于人工HMG-CoA还原酶抑制剂中的β-羟基-δ-内酯。
• Synthesis of Artificial HMG-CoA Reductase Inhibitors Based on the Olefination Strategy
  作者：Tamejiro Hiyama、Tatsuya Minami、Kyoko Takahashi

  DOI：10.1246/bcsj.68.364

  日期：1995.1

  Synthetic methods were studied for optically active 6-oxo-3,5-isopropylidenedioxyhexanoate esters (4), which could be used as a key precursor of various kinds of artificial analogs of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. An enantiomer (+)-4 was prepared by asymmetric reduction of β,δ-diketo esters derived from the Taber’s alcohol or l-tartrate followed by a series of chemical transformations, and the desired enantiomer (−)-4 was prepared by the same asymmetric reduction starting from d-tartrate. The key intermediate (−)-4 was finally converted into a highly potent HMG-CoA reductase inhibitor, NK-104.

  研究了合成光学活性6-氧代-3,5-异丙基二氧六酸酯（4）的方法，这些化合物可作为各种人工类3-羟基-3-甲基戊二酸酰辅酶A（HMG-CoA）还原酶抑制剂的关键前体。通过对来自塔贝酒精或l-酒石酸盐的β,δ-二酮酯进行不对称还原，制备了对映异构体(+)-4，随后经过一系列化学转化，最终得到所需的对映异构体(−)-4，并通过相同的不对称还原方法从d-酒石酸盐出发制得。关键中间体(−)-4最终转化为一种高效的HMG-CoA还原酶抑制剂NK-104。
• A facile entry to β,δ-diketo and syn-β,δ-dihydroxy esters
  作者：Takeshi Hanamoto、Tamejiro Hiyama

  DOI：10.1016/s0040-4039(00)82375-8

  日期：1988.1
• Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
  作者：S. Y. Sit、R. A. Parker、I. Motoc、W. Han、N. Balasubramanian、J. D. Catt、P. J. Brown、W. E. Harte、M. D. Thompson、J. J. Wright

  DOI：10.1021/jm00173a013

  日期：1990.11

  A series of 9,9-bis(4-fluorophenyl)-3,5-dihydroxy-8-(alkyltetrazol-5-yl)- 6,8-nonadienoic acid derivatives 1 were synthesized and found to inhibit competitively the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. The analogues having 1N-methyltetrazol-5-yl attached to the C8-position (3a, 4a, R1 = R2 = F) are the most active in suppressing cholesterol biosynthesis in both in vitro and in vivo models: the IC50 for the chiral form of 3a is 19 nM, Ki = 4.3 x 10(-9)M when Km for HMG-CoA is 28 x 10(-6) M;1 the ED50 (oral) value corresponding to the lactone derivative (4a, BMY 22089) is approximately 0.1 mg/kg. Further, BMY 21950 is nearly 2 orders of magnitude more active in parenchymal heptaocytes, from which most of the serum cholesterol originates, than in other cell preparations (such as spleen, testes, ileum, adrenal, and ocular lens epithelial cells; Table III). This apparent tissue specificity may be highly beneficial since the blocking of cholesterol biosynthesis in other vital organs could eventually lead to undesirable side effects. In addition to the chemical synthesis and biological evaluation, a theoretical study aimed at relating the HMG-CoA reductase inhibitory potency to the three-dimensional structure of the inhibitors was undertaken. With a combination of molecular mapping and 3D-QSAR techniques, it was possible to determine a logical candidate for the conformation of the bound inhibitor and to quantitatively relate inhibitory potency to the shape and size of both the binding site and the C8-substituent.
• A novel enantioselective synthesis of HMG Co-A reductase inhibitor NK-104 and a related compound
  作者：Tatsuya Minami、Tamejiro Hiyama

  DOI：10.1016/s0040-4039(00)60814-6

  日期：——

  Optically active methyl 6-oxo-3.5-syn-isopropylidenedioxyhexanoate (5) was prepared by enantioselective syn-reduction of beta,delta-diketo ester 2, followed by hydrolysis, protection of the diol moiety and ozonolysis, and was converted into a highly potent HMG Co-A reductase inhibitor NK-104 and an analogue.